Author

Antonia Müller

University of BaselPrimary ORCID profile (0000-0002-1105-5010 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Antonia MülleriD2 papers · Philipps University of Marburg

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Christoph DehioiD· 2 shared Cinzia FinoiD· 2 shared Sarah Tschudin‐SutteriD· 2 shared Steffi Klimke· 2 shared Amanzhol KurmasheviD· 1 shared Andreas R. HierlemanniD· 1 shared Benjamin Sellner· 1 shared Carlos FloresiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Christoph DehioORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Perfusable 3D human urothelial model for real-time analysis of bacterial infection dynamics and therapeutic interventions

Amanzhol Kurmashev, Isabel Sorg, Julia Alicia Boos, Lara Grassi, Benjamin Sellner, Cinzia Fino, Mehmet Girgin, Antonia Müller, Steffi Klimke, Sarah Tschudin‐Sutter, Andreas R. Hierlemann, Christoph Dehio

This paper develops a 3D human urothelial model to study UTI dynamics and therapeutic responses in real-time.

bioRxiv · Nov 12, 2025 · PreprintBioengineering

Genome-scale CRISPRi profiling reveals metabolic vulnerabilities of uropathogenic Escherichia coli in human urine

Monica Ortelli, Rūta Prakapaitė, Antonia Müller, Solange Miele, Cinzia Fino, Steffi Klimke, Sarah Tschudin‐Sutter, Urs Jenal, Carlos Flores, David Bikard, Christoph Dehio

This study uses CRISPRi to identify metabolic vulnerabilities of UPEC in urine, highlighting ALS II as a druggable target.

bioRxiv · Oct 31, 2025 · PreprintMicrobiology